Boston Scientific Commences NAVIGATE-PF Trial of the Farawave Nav Pulsed Field Ablation Catheter and Faraview Software Module in Atrial Fibrillation Patients
Shots:
- The NAVIGATE-PF trial evaluates the Farawave Nav Pulsed Field Ablation (PFA) Catheter visualized & tracked by the Faraview Software Module in paroxysmal or persistent AF patients (n=~30). The US FDA’s approval is anticipated in H2’24
- In the study, all participants will undergo cardiac mapping while pulmonary vein isolation will be carried out in paroxysmal AF & additional posterior wall isolation will be performed in persistent AF patients
- The Farawave Nav PFA Catheter introduces magnetic navigation abilities to the Farawave PFA catheter, facilitating detailed mapping & PFA therapy in one device. The Faraview Software Module will visualize mapping data, providing a solution for procedures using the Farapulse PFA System
Ref: Boston Scientific | Image: Boston Scientific
Related News:- The US FDA Grants Approval to Boston Scientific’s Farapulse Pulsed Field Ablation (PFA) System for Atrial Fibrillation (AF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
